Celecoxib is an anti-inflammatory drug of the selective COX-2 inhibitors group. Its more common uses are against rheumatism and chronic pain. Cancer causes chronic inflammation in our bodies (as most, if not all, chronic diseases) and this constant inflammatory stress is a dangerous and important risk factor for the development of new malignant cells. It is an oral drug with different usage protocols.
It has already been proven to have an important effect on the chemoprevention of colon cancer due to its remarkable anti-inflammatory effect, which in the long term may lead to malignant transformation of healthy cells. Because of this important chemopreventive characteristic, it can be used in any cancer type to try to mitigate as much as possible the inflammation process caused by cancer.
Celecoxib addresses an inflammatory process present, to some extent, in all cancer types. For this reason, it can be used by all cancer patients. Even though it doesn’t seem to have any direct effect in cancer cell destruction or any specific metabolic pathways which lead to cell disruption, it seems to contribute to making the cancer microenvironment less rich for the disease progression.
We strongly recommend the short-term use of celecoxib as part of a comprehensive anti-cancer program. It has no direct anti-neoplastic features but is of paramount importance in the chemoprevention and in trying to modulate the chronic inflammation caused by cancer, which leads to protein destruction by the body as well as to higher risk due to the elevated metabolic stress that it brings to the cells.